This week: the biggest regulatory shake-up peptides have had in years, translated into plain English, and a tanning claim that earns the hardest grade we give.

Let's go. ☕

Washington is rewriting the peptide rulebook

Two government moves are colliding this fall, and between them they touch nearly everything this newsletter covers. Here's what happened and what it does and does not change, in four parts.

What actually happened

Two separate events, easy to blur together. The first came this summer: the FDA's Pharmacy Compounding Advisory Committee voted, narrowly, to recommend adding six peptides, BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, to the list of substances compounding pharmacies may legally work with, while recommending against a seventh. The FDA has not acted on those recommendations; formal rulemaking is still ahead. The second is this month's news: the Washington Post reported that the administration is crafting plans that would allow the temporary sale of some currently unapproved peptides while new regulations are worked out. A reported plan, from unnamed officials, with no rule published. Put the two together and you get the moment we're in: the rules around peptides are visibly in motion, and nothing has actually changed yet.

What an advisory vote actually changes

Here is where our four-door framework earns its keep. An advisory committee vote is a recommendation, one step in a multi-step process; the FDA has not finalized anything, and nothing is newly legal today because of it. If the recommendation is eventually adopted, the six peptides would move from the research-only door toward the compounded door: pharmacies could legally prepare them with a prescription. What the vote cannot do, now or ever, is move anything through the approved-drug door. Approval requires clinical trials proving safety and efficacy for a specific condition. Compounding-list eligibility requires no such trials. A peptide can become easier to obtain legally without one new page of evidence that it works.

Access and evidence are separate dials, and only one of them is moving.

Why the timing is uneasy

While these doors are being loosened, the harm receipts keep arriving. In Australia, ABC News testing of black-market peptides found dangerously inconsistent dosing, and doctors there have raised the alarm about a suspected contaminated counterfeit batch after a string of acute liver damage cases, including products sold under the name of a drug that is still in clinical trials. Add the melanoma case report involving a gym-sourced tanning peptide (graded below) and the picture is consistent: the gray market cannot tell you what is in the vial. None of that is an argument that regulated compounding is the same as a gray-market vial; it is the opposite of the same, and that distinction is the point of the compounding pathway. But a regulatory loosening announced into a market this messy puts more weight than ever on the one question regulators cannot answer for you: what is the evidence for this compound, for my use, in people like me?

What this means for the woman reading this

Practically, almost nothing has changed yet, and that is the headline the marketing will not give you. No peptide became FDA-approved. No new evidence appeared. If a clinic, telehealth funnel, or supplement-adjacent brand starts citing “the FDA vote” as validation in the coming months, and they will, remember what the vote was: a recommendation about which door a compound may someday be dispensed through, not a verdict that it works or that it is safe. The vote is worth watching precisely because we are watching it for you: the FDA's formal response is the real event, and it has not happened yet.

What to do with this

• When marketing invokes the FDA, ask the only question that matters: is this product FDA-approved for the use being sold? For every peptide in this story, the answer is no.
• The four-door test survives the rule change: approved drug, cosmetic or supplement, compounded preparation, or research-only product. A door switch changes access, not evidence.
• If you use or are considering a compounded peptide, the questions stay the same: which pharmacy makes it, under what pathway, and what human evidence supports it for your use?
• Suspected reactions to any peptide product can be reported to FDA MedWatch. This is also the mechanism that keeps harm visible while the rules are in flux.

Access may be moving. The evidence, especially the evidence in women, is not moving with it.

“Tanning peptides give you a safe tan without the sun damage.”

What the evidence says. This week a case report made the rounds: a man developed a new melanoma after injecting a tanning peptide he got at his gym. A case report is not proof of causation, and we will not pretend it is. But the claim fails long before the case report arrives. Melanotan II, the compound behind most of these products, is not FDA-approved for anything, has no legitimate compounding pathway, and circulates only through gray-market channels, as injectables and nasal sprays, which means no verified identity, sterility, or dose.

Its mechanism is stimulating melanocytes, the very cells melanoma arises from, and dermatology literature has flagged reports of changing moles and new pigmented lesions in users for years. “Safe tan” is a claim that would require safety trials. There are none. What there is: an unregulated injectable, a plausible mechanism for harm, and now one more case report pointing the wrong direction.

The fair version of the claim: none, really. If the goal is a tan without UV damage, that product already exists, is regulated as a cosmetic, and goes on with a mitt. Self-tanner is boring. Boring is the point.

Worth your inbox

Researching health for yourself is one job. Doing it for an aging parent at the same time is two. GrayBrief is a plain-English education resource for adult children navigating elder care: what to ask, what to watch for, and what nobody tells you until it's urgent. If that's your season of life, it's worth a look.

Not yet, and even if this process finishes, “approved” will still be the wrong word. What happened is that an FDA advisory committee recommended adding six peptides to the list of substances compounding pharmacies may prepare. That is a recommendation the FDA has not finalized, so nothing has changed at your pharmacy. And if it is finalized, it changes the legal access route, not the evidence: compounding-list eligibility does not require the clinical trials that drug approval does. So a compound like BPC-157 could someday be legally compounded with a prescription while still having no controlled human trial showing it works for the uses people buy it for.

What I would watch for as a pharmacist: marketing that collapses this distinction, because “FDA advisory committee recommended for compounding eligibility” will get shortened to “FDA-approved” by people with something to sell. The questions that protect you stay the same in every regulatory weather: is this product approved for my use, which pharmacy is making it and under what pathway, and what human evidence exists for what I'm hoping it does?

Mais, PharmD, Medical Reviewer, Pep in Her Step

• “Has my GLP-1 stopped working?” Plateaus, restarts, and the non-responder question, properly answered.
• Pill versus pen: what the oral semaglutide data actually shows.
• Waking at 3am on a GLP-1: the sleep disruption cluster nobody warned anyone about.